Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Regenerative VEGF-D gene therapy for refractory angina (phase II)
2017-000789-31Phase 2Active
- Sponsor
- Kuopio University Hospital Heart Center
- Start
- Jul 2017
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in angina pectoris comparing AdsVEGF-DΔNΔC gene therapy with Placebo control (2 arms). Primary endpoint: Improvement in functional capacity (6-minute walking test). Started Jul 2017; status: active.
02
Drugs
AdvVEGF-D
03
Conditions
angina pectoris
Beyond the preview
Go deeper on 2017-000789-31.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000789-31.